Amicus Therapeutics (NASDAQ:FOLD) Reaches New 1-Year High – Should You Buy?

Amicus Therapeutics, Inc. (NASDAQ:FOLD) shares hit a new 52-week high during mid-day trading on Monday . The company traded as high as $14.43 and last traded at $14.4250, with a volume of 35649 shares changing hands. The stock had previously closed at $14.43.

Wall Street Analyst Weigh In

Several research firms recently issued reports on FOLD. Cantor Fitzgerald cut shares of Amicus Therapeutics from an “overweight” rating to a “hold” rating and cut their price objective for the stock from $21.00 to $14.50 in a research report on Friday, December 19th. Citigroup reiterated a “neutral” rating and issued a $14.50 target price (down from $17.00) on shares of Amicus Therapeutics in a report on Monday, December 22nd. Guggenheim cut shares of Amicus Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Monday, January 5th. TD Cowen lowered shares of Amicus Therapeutics from a “buy” rating to a “hold” rating and set a $14.50 price target on the stock. in a research report on Monday, December 22nd. Finally, Zacks Research cut Amicus Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Monday, January 26th. Three investment analysts have rated the stock with a Buy rating, nine have issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Hold” and a consensus target price of $15.39.

Amicus Therapeutics Trading Up 0.2%

The company has a market cap of $4.54 billion, a PE ratio of -180.75 and a beta of 0.43. The company’s 50 day simple moving average is $14.34 and its two-hundred day simple moving average is $11.75. The company has a debt-to-equity ratio of 1.43, a current ratio of 2.84 and a quick ratio of 1.88.

Amicus Therapeutics (NASDAQ:FOLD) last released its quarterly earnings results on Friday, February 20th. The biopharmaceutical company reported $0.10 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.13 by ($0.03). Amicus Therapeutics had a negative net margin of 4.27% and a positive return on equity of 4.15%. The company had revenue of $185.21 million during the quarter, compared to analysts’ expectations of $185.00 million. During the same period last year, the firm posted $0.09 earnings per share. Amicus Therapeutics’s revenue was up 23.7% on a year-over-year basis. As a group, sell-side analysts anticipate that Amicus Therapeutics, Inc. will post 0.15 EPS for the current fiscal year.

Insider Transactions at Amicus Therapeutics

In other Amicus Therapeutics news, CEO Bradley L. Campbell sold 22,500 shares of the business’s stock in a transaction that occurred on Monday, March 2nd. The stock was sold at an average price of $14.35, for a total value of $322,875.00. Following the sale, the chief executive officer owned 998,680 shares of the company’s stock, valued at $14,331,058. The trade was a 2.20% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 2.20% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently modified their holdings of the company. Osaic Holdings Inc. raised its holdings in shares of Amicus Therapeutics by 450.1% in the 2nd quarter. Osaic Holdings Inc. now owns 4,104 shares of the biopharmaceutical company’s stock valued at $25,000 after buying an additional 3,358 shares during the period. EverSource Wealth Advisors LLC boosted its holdings in Amicus Therapeutics by 472.6% during the 2nd quarter. EverSource Wealth Advisors LLC now owns 4,455 shares of the biopharmaceutical company’s stock valued at $26,000 after acquiring an additional 3,677 shares during the period. Farther Finance Advisors LLC boosted its holdings in Amicus Therapeutics by 2,651.5% during the 4th quarter. Farther Finance Advisors LLC now owns 1,871 shares of the biopharmaceutical company’s stock valued at $27,000 after acquiring an additional 1,803 shares during the period. GAMMA Investing LLC grew its position in Amicus Therapeutics by 167.1% in the 4th quarter. GAMMA Investing LLC now owns 1,987 shares of the biopharmaceutical company’s stock valued at $28,000 after acquiring an additional 1,243 shares in the last quarter. Finally, Strs Ohio acquired a new position in Amicus Therapeutics in the 1st quarter valued at about $30,000.

About Amicus Therapeutics

Amicus Therapeutics (NASDAQ:FOLD) is a biopharmaceutical company focused on the discovery, development and commercialization of treatments for rare and orphan diseases. The company specializes in pharmacological chaperones and gene therapy approaches designed to address the underlying causes of lysosomal storage disorders. Its proprietary technology platform integrates structure?based drug design with precision medicine to identify small molecules that stabilize misfolded proteins and restore cellular function.

The company’s lead marketed product, Galafold (migalastat), is an oral pharmacological chaperone approved in the United States, European Union and other territories for the treatment of Fabry disease in patients with amenable genetic variants.